Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

9.1%

1 terminated/withdrawn out of 11 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

1 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

7(63.6%)

Phase 2

3(27.3%)

Phase 3

1(9.1%)

11Total

Phase 1(7)

Phase 2(3)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials

NCT06062420Phase 2Active Not Recruiting

A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

Role: collaborator

NCT05565378Phase 2Active Not Recruiting

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

Role: collaborator

NCT04446351Phase 1Active Not Recruiting

Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

Role: collaborator

NCT06472076Phase 3Active Not Recruiting

A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

Role: collaborator

NCT06547957Phase 1Active Not Recruiting

A First-in-Human Study of EOS301984 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors

Role: lead

NCT05403385Phase 2Active Not Recruiting

Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

Role: lead

NCT05289492Phase 1Terminated

Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma

Role: lead

NCT03873883Phase 1Completed

First-in-Human Study of EOS100850 (Inupadenant) in Patients with Cancer